GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The therapy also delivered significant improvements in key liver enzyme markers
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
NEJM study shows strong protection across strains
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Subscribe To Our Newsletter & Stay Updated
